by John Conrad | Apr 29, 2026 | Member News
Emalex Biosciences has been acquired by Teva Pharmaceutical Industries, marking a significant milestone for the company and its lead neuroscience program. The acquisition is centered on Emalex’s first-in-class, NDA-ready therapy targeting Tourette syndrome and related...
